iwCLL 2021 | Understanding patient perspectives in CLL treatment
Brian Koffman, MDCM (retired), MS Ed, CLL Society, Inc., Chula Vista, CA, shares his insights into patient perspectives on the changing chronic lymphocytic leukemia (CLL) treatment landscape. Dr Koffman reports that a study found that patients were more likely to be aware of 17p status than complex karyotype or notch-1 status and that despite more than half of patients self-reporting an understanding of measurable residual disease (MRD), a significant proportion expressed a preference for MRD testing at clinically inappropriate times. Other findings include continued remission being viewed as the most important benefit of limited-duration therapy. As CLL treatment evolves to increasingly incorporate MRD testing, extra care needs to be taken to ensure that CLL patients are properly informed on CLL disease management. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
